Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson

doi:10.1182/blood-2016-06-718106

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

DOI PDF 被引用文献1件

Chaitra S. Ujjani

Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC;
Sin-Ho Jung

Alliance Statistics and Data Center, Duke University, Durham, NC;
Brandelyn Pitcher

Alliance Statistics and Data Center, Duke University, Durham, NC;
Peter Martin

Meyer Cancer Center, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY;
Steven I. Park

UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC;
Kristie A. Blum

Division of Hematology, The Ohio State University, Columbus, OH;
Sonali M. Smith

University of Chicago Medicine Comprehensive Cancer Center, University of Chicago, Chicago, IL;
Myron Czuczman

Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY;
Matthew S. Davids

Dana-Farber/Partners CancerCare, Boston, MA;
Ellis Levine

Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY;
Lionel D. Lewis

Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, NH;
Scott E. Smith

Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL; and
Nancy L. Bartlett

Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
John P. Leonard

Meyer Cancer Center, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY;
Bruce D. Cheson

Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC;

説明

<jats:title>Key Points</jats:title> <jats:p>The combination of rituximab, lenalidomide, and ibrutinib is associated with a high incidence of rash in follicular lymphoma (all grades 82%). Efficacy of the triplet appears similar to rituximab-lenalidomide in the same patient population.</jats:p>